Business context and reporting period
GSI Group Inc. filed this unaudited Form 10-Q for the quarter ended March 28, 2014. The filing describes a manufacturer of precision photonic and motion-control components serving medical and advanced industrial OEM markets, with Laser Products, Medical Technologies, and Precision Motion segments. The filing identifies the registrant as GSI Group Inc.; it does not identify it as Novanta Inc.
Financial performance and liquidity
Unless otherwise noted, amounts are in U.S. dollars. Comparative results are for the three months ended March 29, 2013.
| Metric | Q1 2014 | Prior period |
|---|---|---|
| Sales | $79.1 million | $75.1 million |
| Gross profit / margin | $32.1 million / 40.6% | $30.6 million / 40.8% |
| Operating income | $4.1 million | $1.5 million |
| Income from continuing operations | $2.9 million | $1.7 million |
| Net income attributable to GSI Group | $1.0 million; $0.03 per diluted share | $2.1 million; $0.06 per diluted share |
| Cash from continuing operating activities | $2.8 million | $6.3 million |
- Sales increased 5.4%; management attributed 2.9 percentage points to JADAK and 1.1 points to favorable foreign exchange, leaving 1.4% organic growth.
- Operating margin rose to 5.1% from 1.9%, aided by higher gross profit and lower restructuring and acquisition-related costs. Gross margin edged down 0.2 percentage points.
- Discontinued operations reported a $1.9 million net loss, including a $1.6 million pretax fair-value write-down of the Scientific Lasers business. This reduced consolidated net income despite improved continuing-operations income.
- Cash and equivalents were $31.7 million at quarter-end, down from $61.0 million at year-end. The company reported $79.0 million of unused availability on its revolving facility.
- Total debt was $136.6 million, comprising $40.6 million term debt and $96.0 million revolver borrowings, versus $71.5 million at year-end. The $70 million revolver draw largely funded the JADAK acquisition. Capital spending was $1.0 million.
- Current assets were $192.1 million and current liabilities $64.0 million. Operating cash flow from continuing operations declined by $3.5 million year over year, which management attributed primarily to working-capital timing.
Material changes and unusual items
- On March 14, 2014, GSI acquired JADAK for approximately $93.5 million in cash, subject to working-capital adjustments. JADAK contributed $2.2 million of sales and a $0.1 million loss from continuing operations after acquisition. The preliminary allocation included $44.0 million goodwill and $40.5 million identifiable intangible assets.
- The company amended its credit agreement, increasing the revolving commitment from $75 million to $175 million and raising the maximum leverage covenant to 3.00. At quarter-end, actual leverage was 2.24 against a 3.00 maximum; fixed-charge coverage was 4.92 against a 1.50 minimum. The company reported covenant compliance.
- Medical Technologies sales fell 5.1%, with lower visualization and imaging-informatics volumes related to OEM dual sourcing; JADAK partly offset the decline. Laser Products and Precision Motion sales rose 9.7% and 11.7%, respectively.
- Foreign-exchange results shifted from a $1.2 million gain in the prior-year quarter to a small loss in Q1 2014. The effective tax rate was 24.7%, versus 18.7%.
- On January 31, GSI signed a letter of intent to sell its Scientific Lasers business for $7.5 million cash, plus up to $3.0 million contingent consideration tied to 2014 revenue targets. The sale remained subject to due diligence, a definitive agreement, and customary closing conditions; management expected completion by year-end.
Outlook, commentary, and risks
Management gave no specific numerical earnings or revenue guidance in the supplied filing text. It stated that operating cash flows and available revolver capacity were expected to meet operating and investing needs for at least the next 12 months. Its strategy emphasizes increasing medical-market exposure, expanding products through acquisitions and development, and improving operational efficiency. The company cautioned that actual results may differ materially from forward-looking statements.
Disclosed risks include customer capital-spending cyclicality and order timing, acquisition integration and realization of expected benefits, foreign-exchange and interest-rate movements, debt-service and covenant capacity, access to subsidiary cash, product and supply disruptions, and the ability to protect intellectual property and commercialize new products. Ordinary-course legal claims were not expected by management to have a material adverse effect, though no assurance was given. Management reported effective disclosure controls and no material quarter-end change in internal control over financial reporting.
Investor verification priorities
- Verify the issuer and security identity: this filing names GSI Group Inc., not Novanta Inc.
- Check JADAK’s final purchase-price allocation, working-capital settlement, integration progress, and contribution to subsequent results.
- Confirm the status and final terms of the proposed Scientific Lasers sale and any contingent consideration.
- Monitor cash generation, revolver usage, debt service, covenant headroom, and the effect of acquisition-related borrowing.
- Assess whether Medical Technologies can recover from OEM dual sourcing and whether reported growth persists organically, excluding acquisitions and currency effects.